奥美拉唑
兰索拉唑
埃索美拉唑
质子抑制剂泵
中止
胃酸
幽门螺杆菌
医学
胃肠病学
泮托拉唑
雷贝拉唑
内科学
胃
作者
Michaël Rochoy,Sébastien Dubois,R. Glantenet,Sophie Gautier,David Saadoun
出处
期刊:Therapie
[Elsevier]
日期:2018-05-01
卷期号:73 (3): 237-246
被引量:10
标识
DOI:10.1016/j.therap.2017.08.005
摘要
Since the introduction of the first proton pump inhibitor (PPI) 20 years ago, studies have examined the presence of a rebound effect when this treatment is discontinued. These studies are heterogeneous and contradictory: the last literature review on the rebound in gastric acidity dates from 2006 and did not allow to conclude on the subject. Our objective was to carry out an up-to-date literature review on the existence and characteristics of this gastric acid rebound at the end of PPIs.We conducted a review of the literature on the gastric acid rebound, without excluding the design of the studies. The Medline® databases (PubMed), ISI (Web Of Science) and Google Scholar were queried using the following equation: ("inhibitor proton pump" OR omeprazole OR esomeprazole OR lansoprazole OR pantoprazole OR rabeprazole) AND "rebound" AND "Acid hypersecretion". Only studies with a measure (whatever it was) before and after treatment were analyzed.Of the 131 publications identified, 10 were selected. The design of the studies was very heterogeneous. Five studies concluded a rebound effect. Studies with a treatment duration of less than 4 weeks did not demonstrate a rebound effect. The colonization with Helicobacter pylori masked the appearance of the rebound.Daily PPI exposure for more than 4 weeks is likely to trigger a rebound of acid hypersecretion about 15 days after discontinuation, and lasting from a few days to several weeks depending on the duration of the exposure.
科研通智能强力驱动
Strongly Powered by AbleSci AI